CN111138420A - C13Isotope labeled lapatinib synthesis method - Google Patents

C13Isotope labeled lapatinib synthesis method Download PDF

Info

Publication number
CN111138420A
CN111138420A CN202010084702.8A CN202010084702A CN111138420A CN 111138420 A CN111138420 A CN 111138420A CN 202010084702 A CN202010084702 A CN 202010084702A CN 111138420 A CN111138420 A CN 111138420A
Authority
CN
China
Prior art keywords
compound
reaction
lapatinib
isotopically labeled
carrying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010084702.8A
Other languages
Chinese (zh)
Inventor
邓德轩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Kaijite Pharmaceutical Technology Development Co Ltd
Original Assignee
Beijing Kaijite Pharmaceutical Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Kaijite Pharmaceutical Technology Development Co Ltd filed Critical Beijing Kaijite Pharmaceutical Technology Development Co Ltd
Priority to CN202010084702.8A priority Critical patent/CN111138420A/en
Publication of CN111138420A publication Critical patent/CN111138420A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Abstract

The invention relates to the technical field of drug synthesis, in particular to a C13A method for synthesizing isotopically labeled lapatinib. The method comprises the following steps: carrying out nitration reaction on the compound 1 to obtain a compound 2; the compound 2 is hydrolyzed to obtain a compound 3; the compound 3 is subjected to chlorination reaction to obtain a compound 4; the compound 4 is subjected to substitution reaction to obtain a compound 5; the compound 5 is subjected to reduction reaction to obtain a compound 6; the compound 6 is subjected to substitution reaction to obtain a compound 7; compound 7 is coupled to obtain C13Labeling lapatinib internal standard isotope labeling substance. The method has the advantages of simple technical route, mild conditions, no use of reagents with high danger and high separation difficulty, environmental protection and high application value.

Description

C13Isotope labeled lapatinib synthesis method
Technical Field
The invention relates to the technical field of drug synthesis, in particular to a C13A method for synthesizing isotopically labeled lapatinib.
Background
Lapatinib is a new breast cancer targeted therapy drug developed by glatiramer britain, is a tyrosine kinase inhibitor, and can effectively inhibit the activities of human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor receptor-2 (ErbB2) tyrosine kinase. It is unique in that it can act in a variety of ways to inhibit or kill tumor cells by preventing breast cancer cells from receiving signals necessary for growth. Currently, in China, lapatinib is mainly used as a first-line treatment drug for trastuzumab-resistant patients. As stable isotopes of C13The marked lapatinib internal label isotope marker is widely applied to lapatinib pharmacy and clinical research and has wide application prospect, so that research on a synthetic method of the lapatinib internal label isotope marker has important significance on clinical application of the lapatinib internal label isotope marker.
Disclosure of Invention
In view of the above technical problems, the present invention provides a method for preparing C13The synthesis method of the labeled lapatinib internal standard isotope label has the advantages of simple technical route, mild conditions, no use of reagents with high risks and high separation difficulty, environmental friendliness and high application value.
The present invention relates to the preparation of the following compounds:
Figure BDA0002381639890000021
the following synthetic route is specifically adopted:
Figure BDA0002381639890000022
the method specifically comprises the following steps:
step a): carrying out nitration reaction on the compound 1 to obtain a compound 2;
step b): hydrolyzing the compound 2 to obtain a compound 3;
step c): performing chlorination reaction on the compound 3 to obtain a compound 4;
step d): carrying out substitution reaction on the compound 4 to obtain a compound 5;
step e): carrying out reduction reaction on the compound 5 to obtain a compound 6;
step f): carrying out substitution reaction on the compound 6 to obtain a compound 7;
step g): the compound 7 is subjected to coupling reaction to obtain C13Isotopically labeled lapatinib.
Further, the step a) is as follows: carrying out nitration reaction by using the compound 1 as a reaction substrate and potassium nitrate as a nitration reagent to obtain a compound 2.
Further, the hydrolysis reagent in step b) is one of potassium hydroxide, sodium hydroxide or tetrabutylammonium hydroxide.
Further, the reaction conditions of the hydrolysis reaction of the step b) are 70-80 ℃, and preferably 80 ℃.
Further, the step c) is as follows: and taking the compound 3 as a reaction substrate, adding NCS as a chlorination reagent, and carrying out chlorination reaction to obtain a compound 4.
Further, the step d) is as follows: and (3) taking the compound 4 as a reaction substrate, and adding potassium carbonate and acetonitrile to perform substitution reaction to obtain a compound 5.
Further, in the step e), the compound 5 is used as a reaction substrate, and iron powder and ammonium chloride are added into the reaction substrate to perform reduction reaction in an ethanol solution to obtain a compound 6.
Further, the step f) is as follows: and (3) taking the compound 6 as a reaction substrate, adding 6-iodo-4-chloroquinazoline and isopropanol, and carrying out substitution reaction to obtain a compound 7.
Further, the step g) is as follows: taking the compound 7 as a reaction substrate, adding lapatinib furan boronic acid intermediate, dioxane, water, a catalyst and potassium acetate to perform coupling reaction to obtain C13Isotopically labeled lapatinib.
Further, the catalyst in the step g) is palladium tetratriphenylphosphine, and the chemical formula of the Lapatinib furoic acid intermediate is as follows:
the invention has the beneficial effects that: the method has the advantages of simple technical route, cheap and easily-obtained raw materials, mild reaction conditions, easy monitoring, no use of reagents with high separation difficulty, environmental protection, high application value and suitability for industrial large-scale production.
Detailed Description
The technical solution of the present invention will be described in detail with reference to the specific embodiments. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
The invention relates to a compound C13Method for synthesizing isotopically labeled lapatinib, the C13The chemical formula of isotopically labeled lapatinib is as follows:
Figure BDA0002381639890000041
the invention provides a compound C13The synthesis method of isotopically labeled lapatinib comprises the following reaction route:
Figure BDA0002381639890000042
the method comprises the following steps:
step a): carrying out nitration reaction on the compound 1 to obtain a compound 2;
step b): hydrolyzing the compound 2 to obtain a compound 3;
step c): performing chlorination reaction on the compound 3 to obtain a compound 4;
step d): carrying out substitution reaction on the compound 4 to obtain a compound 5;
step e): carrying out reduction reaction on the compound 5 to obtain a compound 6;
step f): carrying out substitution reaction on the compound 6 to obtain a compound 7;
step g): compound 7 is coupled to obtain C13Labeling lapatinib internal standard isotope labeling substance.
The following are specific examples of the present invention:
example 1
Step a): synthesis of Compound 2
Figure BDA0002381639890000051
Adding the compound 1(1.00g, 0.09mmol) and 50ml of n-hexane into a 100ml single-neck flask, cooling to 5 ℃, adding potassium nitrate (1.00g,0.11 mol) while stirring, reacting for 12h, pouring the system into a mixed solution of 50ml of dichloromethane and 50ml of ice water, stirring for 10min, separating an organic phase, and performing column chromatography purification by evaporation to obtain a product compound 2(754mg), wherein the yield is 54.0%.
Example 2
Step b): synthesis of Compound 3
Figure BDA0002381639890000052
Adding 2ml of compound 2(600mg, 0.038mmol) water into a 100ml reaction bottle, adding 10ml of tetrahydrofuran and 10ml of tetrabutylammonium hydroxide, heating to 80 ℃ for reaction for 3 hours, cooling to room temperature, extracting the system with dichloromethane three times, 50ml each time, combining organic phases, evaporating to dryness, and purifying by column chromatography to obtain a product compound 3(517mg), wherein: 97.5 percent.
Example 3
Step c): synthesis of Compound 4
Figure BDA0002381639890000053
Compound 3(500mg, 0.036mmol) was dissolved in 10ml acetonitrile and 10ml glacial acetic acid and NCS (470mg, 0.031mmol) was added and stirred at 80 ℃ until dissolved. The reaction system was stirred for 1 hour, 2ml of water was added, and the resulting mixture was purified by column chromatography to dryness to give the product compound 4(397mg) in yield: and (3.8).
Example 4
Step d): synthesis of Compound 5
Figure BDA0002381639890000061
Compound 4(400mg, 0.023mmol) and 3-fluorobenzyl bromide (440mg, 0.023mmol) acetonitrile 50ml are added into a 100ml reaction flask, anhydrous potassium carbonate (635mg,0.046mmol) is added, the system reacts for 3 hours at 80 ℃, then the filtration is carried out, the filter cake is rinsed by 20ml acetonitrile, the filtrate is evaporated to dryness, and the column chromatography purification is carried out to obtain the product compound 5(415mg), the yield: 64.1 percent.
Example 5
Step e): synthesis of Compound 6
Figure BDA0002381639890000062
Adding a compound 5(600mg, 0.021mmol), iron powder (597mg, 0.11mmol) and ammonium chloride (590mg, 0.11mmol) into a 100ml reaction bottle, adding 50ml of ethanol and 5ml of water, reacting at 80 ℃ for 6 hours, cooling to room temperature after the reaction is finished, filtering, rinsing a filter cake with 20ml of ethanol, adding 50ml of dichloromethane into the filter cake, stirring for 20 minutes, filtering, evaporating the filtrate to dryness, and purifying by column chromatography to obtain a product compound 6 (303mg), wherein the yield is as follows: 56.5 percent.
Example 6
Step f): synthesis of Compound 7
Figure BDA0002381639890000063
Adding a compound 6(300mg, 0.012mmol) and 6-iodo-4-chloroquinazoline (345mg, 0.012mmol) into a three-necked flask, adding isopropanol, reacting at 80 ℃ for 3 hours, cooling to room temperature after the reaction is finished, filtering, rinsing a filter cake with 20ml of cold isopropanol, and drying the filter cake to obtain a compound 7(501mg) with yield: 83.2 percent.
Example 7
Step g): c13Synthesis of isotopically labeled lapatinib
Figure BDA0002381639890000071
Adding a compound 7(500mg, 0.099mmol) and a lapatinib furanboronic acid intermediate (247mg, 0.099mmol) into a three-necked flask, adding 20ml of dioxane, 2ml of water, palladium tetratriphenylphosphine (15mg, 0.0099mmol), adding potassium acetate (192mg, 0.02mmol) to provide an alkaline environment, reacting at 80 ℃ for 3 hours, cooling to room temperature after the reaction is finished, filtering, and purifying a filtrate evaporation system by column chromatography to obtain a product C13Labeled lapatinib internal standard isotope label (269mg), yield: 52.5 percent.
Wherein the lapatinib furanboronic acid intermediate is:
Figure BDA0002381639890000072

Claims (10)

1. c13The method for synthesizing isotopically labeled lapatinib is characterized by comprising the following steps of:
Figure FDA0002381639880000011
in the step a), carrying out nitration reaction on the compound 1 to obtain a compound 2;
step b), carrying out hydrolysis reaction on the compound 2 to obtain a compound 3;
in the step c), the compound 3 is subjected to chlorination reaction to obtain a compound 4;
in the step d), the compound 4 is subjected to substitution reaction to obtain a compound 5;
step e), carrying out reduction reaction on the compound 5 to obtain a compound 6;
step f), carrying out substitution reaction on the compound 6 to obtain a compound 7;
step g) coupling of the compound 7 to give C13Isotopically labeled lapatinib.
2. A compound of claim 113The method for synthesizing isotopically labeled lapatinib is characterized in that the step a) is as follows: carrying out nitration reaction by using the compound 1 as a reaction substrate and potassium nitrate as a nitration reagent to obtain a compound 2.
3. A compound of claim 113The synthesis method of isotopically labeled lapatinib is characterized by comprising the following steps: the hydrolysis reaction reagent in the step b) is one of potassium hydroxide, sodium hydroxide or tetrabutylammonium hydroxide.
4. A compound of claim 313The synthesis method of isotopically labeled lapatinib is characterized by comprising the following steps: the hydrolysis temperature of the step b) is 70-80 ℃.
5. A compound of claim 113The method for synthesizing isotopically labeled lapatinib is characterized in that the step c) comprises the following steps: and taking the compound 3 as a reaction substrate, adding NCS as a chlorination reagent, and carrying out chlorination reaction to obtain a compound 4.
6. A compound of claim 113A method for synthesizing isotopically labeled lapatinib is characterized in that,the step d) is as follows: and (3) taking the compound 4 as a reaction substrate, and adding potassium carbonate and acetonitrile to perform substitution reaction to obtain a compound 5.
7. A compound of claim 113The method for synthesizing isotopically labeled lapatinib is characterized in that the step e) is as follows: and taking the compound 5 as a reaction substrate, adding iron powder and ammonium chloride into the reaction substrate, and carrying out reduction reaction in an ethanol solution to obtain a compound 6.
8. A process as claimed in claim 713The method for synthesizing isotopically labeled lapatinib is characterized in that the step f) is as follows: and (3) taking the compound 6 as a reaction substrate, adding 6-iodo-4-chloroquinazoline and isopropanol, and carrying out substitution reaction to obtain a compound 7.
9. The method for synthesizing C13 isotopically labeled lapatinib of claim 1, wherein: the step g) is as follows: taking the compound 7 as a reaction substrate, adding lapatinib furan boronic acid intermediate, dioxane, water, a catalyst and potassium acetate to perform coupling reaction to obtain C13Isotopically labeled lapatinib.
10. The method of claim 9, wherein the method for synthesizing C13 isotopically labeled lapatinib comprises the following steps: the catalyst in the step g) is palladium tetratriphenylphosphine, and the chemical formula of the Lapatinib furanoate intermediate is as follows:
Figure FDA0002381639880000021
CN202010084702.8A 2020-02-10 2020-02-10 C13Isotope labeled lapatinib synthesis method Pending CN111138420A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010084702.8A CN111138420A (en) 2020-02-10 2020-02-10 C13Isotope labeled lapatinib synthesis method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010084702.8A CN111138420A (en) 2020-02-10 2020-02-10 C13Isotope labeled lapatinib synthesis method

Publications (1)

Publication Number Publication Date
CN111138420A true CN111138420A (en) 2020-05-12

Family

ID=70527188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010084702.8A Pending CN111138420A (en) 2020-02-10 2020-02-10 C13Isotope labeled lapatinib synthesis method

Country Status (1)

Country Link
CN (1) CN111138420A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2268877C1 (en) * 2004-05-12 2006-01-27 Анатолий Александрович Ермаков Method for preparing 2-chloro-4-nitrophenol
CN1962593A (en) * 2006-11-24 2007-05-16 王在军 Pyrocatechin and hydroquinone production process
CN101759570A (en) * 2009-12-27 2010-06-30 安徽八一化工股份有限公司 Preparation method of p-nitrophenol
CN102321076A (en) * 2011-07-07 2012-01-18 中国科学技术大学 The preparation method of lapatinibditosylate midbody and analogue thereof
CN102532109A (en) * 2010-12-27 2012-07-04 浙江海正药业股份有限公司 Synthetic method of lapatinib and salt of lapatinib
CN103130657A (en) * 2013-02-05 2013-06-05 江苏中旗作物保护股份有限公司 Synthetic method of 2-chloro-4-aminophenol
CN106632276A (en) * 2015-10-28 2017-05-10 上海天慈生物谷生物工程有限公司 Preparation method of medicine for treating breast cancers

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2268877C1 (en) * 2004-05-12 2006-01-27 Анатолий Александрович Ермаков Method for preparing 2-chloro-4-nitrophenol
CN1962593A (en) * 2006-11-24 2007-05-16 王在军 Pyrocatechin and hydroquinone production process
CN101759570A (en) * 2009-12-27 2010-06-30 安徽八一化工股份有限公司 Preparation method of p-nitrophenol
CN102532109A (en) * 2010-12-27 2012-07-04 浙江海正药业股份有限公司 Synthetic method of lapatinib and salt of lapatinib
CN102321076A (en) * 2011-07-07 2012-01-18 中国科学技术大学 The preparation method of lapatinibditosylate midbody and analogue thereof
CN103130657A (en) * 2013-02-05 2013-06-05 江苏中旗作物保护股份有限公司 Synthetic method of 2-chloro-4-aminophenol
CN106632276A (en) * 2015-10-28 2017-05-10 上海天慈生物谷生物工程有限公司 Preparation method of medicine for treating breast cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOHAMED A. B. MOSTAFA等: "《Iron(III)-Catalyzed Chlorination of Activated Arenes》", 《JOURNAL OF ORGANIC CHEMISTRY》, vol. 82, no. 14, pages 7529 - 7537 *

Similar Documents

Publication Publication Date Title
CN102985416A (en) Process of preparing a thrombin specific inhibitor
CN103333942A (en) A synthetic method for (R)-praziquantel
CN113354575B (en) Synthesis method of terbinafine
CN1679586A (en) Novel synthesis and crystallization of piperazine ring-containing compounds
CN111138420A (en) C13Isotope labeled lapatinib synthesis method
CN100348588C (en) Chemical synthesis method of pyrimidine thioketone
CN106636241B (en) Method for preparing esmollin intermediate by enzyme method
CN111909048B (en) Method for synthesizing atorvastatin calcium intermediate by multi-component one-pot method
CN112194581B (en) Preparation method of flurbiprofen axetil
CN112110879B (en) Preparation method of sulcardine free alkali
CN111943874B (en) Aryl naproxen derivative high-valence iodine compound and preparation method and application thereof
CN110041274B (en) Method for preparing 5-fluoroalkyl triazole compound by air oxidation multi-component one-pot method
CN109574830B (en) Rosuvastatin calcium intermediate, and preparation method and application thereof
CN110229111B (en) Ambroxol impurity and preparation method and application thereof
CN105884625A (en) Synthesis method of R-salmeterol
CN111320712A (en) Synthesis method of sugammadex sodium intramolecular thioether impurity
CN108329218A (en) It is a kind of(R)Adrenergic preparation method
CN112300059B (en) Preparation method of PF-06651600 intermediate
WO2023103306A1 (en) Method for preparing deuterated cytidine derivative
CN110386884B (en) Preparation method of florfenicol intermediate compound
CN106749075A (en) Crystal formation of oxazolidone intermediate of Ah Nagqu ripple and preparation method thereof
JPS59116298A (en) Preparation of 6,8-substituted-adenosine-3',5'-cyclic phosphoric acid and its salt
CN111087351A (en) Synthetic method of erlotinib intermediate
CN117088826A (en) Synthesis method of polysubstituted oxazole promoted by visible light
CN115385836A (en) Synthetic method of amino selenate compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination